Critical Survey: Aurora Cannabis (ACB) versus Pharmacyte Biotech (OTCMKTS:PMCB)

Pharmacyte Biotech (OTCMKTS:PMCB) and Aurora Cannabis (NYSE:ACB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Earnings & Valuation

This table compares Pharmacyte Biotech and Aurora Cannabis’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pharmacyte Biotech N/A N/A -$6.82 million N/A N/A
Aurora Cannabis $43.49 million 211.11 $56.66 million $0.12 75.58

Aurora Cannabis has higher revenue and earnings than Pharmacyte Biotech.

Insider and Institutional Ownership

0.2% of Pharmacyte Biotech shares are owned by institutional investors. Comparatively, 8.2% of Aurora Cannabis shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Pharmacyte Biotech and Aurora Cannabis, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharmacyte Biotech 0 0 0 0 N/A
Aurora Cannabis 0 1 3 0 2.75

Aurora Cannabis has a consensus target price of $9.50, indicating a potential upside of 4.74%. Given Aurora Cannabis’ higher possible upside, analysts clearly believe Aurora Cannabis is more favorable than Pharmacyte Biotech.

Volatility & Risk

Pharmacyte Biotech has a beta of 2.3, suggesting that its share price is 130% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 2.9, suggesting that its share price is 190% more volatile than the S&P 500.


This table compares Pharmacyte Biotech and Aurora Cannabis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pharmacyte Biotech N/A -96.25% -84.93%
Aurora Cannabis -57.54% 3.95% 3.43%


Aurora Cannabis beats Pharmacyte Biotech on 8 of the 9 factors compared between the two stocks.

About Pharmacyte Biotech

PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the Cannabis plant. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Laguna Hills, California.

About Aurora Cannabis

Aurora Cannabis Inc. produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution. The company's products consist of dried cannabis and cannabis oil; CanniMed vegan capsules; and hemp products, as well as sells vaporizers, consumable vaporizer accessories, and herb mills for using herbal cannabis products. It also operates CanvasRX, a network of cannabis counseling and outreach centers; and provides cannabis analytical product testing services. The company has operations in 19 countries across five continents. Aurora Cannabis Inc. has collaboration agreements with PharmaChoice, Pharmasave, and Shoppers Drug Mart for the distribution, sale, and marketing of medical cannabis products through their respective networks of pharmacies. The company has a strategic agreements with Hempco Food and Fiber Inc.; CTT Pharmaceuticals Inc.; Choom Holdings Inc.; Capcium Inc.; The Green Organic Dutchman Holdings Ltd.; Société des Alcools du Québec; Alcanna; Radient Technologies; Micron Waste; Wagner Dimas; Evio; and Cann Group Limited. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Receive News & Ratings for Pharmacyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmacyte Biotech and related companies with's FREE daily email newsletter.

Leave a Reply

Leave a Reply